AusCann holds major potential in Australian medicinal market

Australian medicinal cannabis companies instantly saw a stock price increase after the federal government permitted medicinal cannabis. Despite the legislation, many cannabis companies fail to provide investors with reliable financial results. AusCann faces the harsh reality of no sales revenue. Because AusCann has no clinically validated products. However, this could all change in January 2020. Could penny stock AusCann surge next year? - if so, should you get ahead of the game?




**promotion blocked**/2019/10/10/auscann-holds-major-potential-in-australian-medicinal-market/